Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial

British Journal of Haematology

Volumn 177, Issue 4, 2017, Pages 620-629

  Hoppe, Carolyn ^a   Jacob, Eufemia ^b   Styles, Lori ^c   Kuypers, Frans ^d   Larkin, Sandra ^d   Vichinsky, Elliott ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PHARMACYCLICS INC   (United States)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

clinical effect; inflammation; sickle cell anaemia; simvastatin; vaso occlusive pain

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANALGESIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASCULOTROPIN A;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MALE; OPEN STUDY; PAIN; PAIN INTENSITY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SICKLE CELL ANEMIA; SIDE EFFECT; SINGLE DRUG DOSE; VASOOCCLUSIVE PAIN; CLINICAL TRIAL; COMPLICATION; METABOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; BIOMARKERS; C-REACTIVE PROTEIN; CHILD; E-SELECTIN; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; NITRIC OXIDE; PAIN; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 85016444737     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14580     Document Type: Article

References (84)

1. Aisiku, I.P., Smith, W.R., McClish, D.K., Levenson, J.L., Penberthy, L.T., Roseff, S.D., Bovbjerg, V.E. & Roberts, J.D. (2009) Comparisons of high versus low emergency department utilizers in sickle cell disease. Annals of Emergency Medicine, 53, 587–593.
2. Akinsheye, I. & Klings, E.S. (2010) Sickle cell anemia and vascular dysfunction: the nitric oxide connection. Journal of Cellular Physiology, 224, 620–625.
3. Al Najjar, S., Adam, S., Ahmed, N. & Qari, M. (2016) Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease. Annals of Hematology, 96, 141–146.
4. Albert, M.A., Staggers, J., Chew, P. & Ridker, P.M. (2001) The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. American Heart Journal, 141, 893–898.
5. Almeida, C.B., Souza, L.E., Leonardo, F.C., Costa, F.T., Werneck, C.C., Covas, D.T., Costa, F.F. & Conran, N. (2015) Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood, 126, 711–720.
6. Antonopoulos, A.S., Margaritis, M., Lee, R., Channon, K. & Antoniades, C. (2012) Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Current Pharmaceutical Design, 18, 1519–1530.
7. Bao, W., Hu, E., Tao, L., Boyce, R., Mirabile, R., Thudium, D.T., Ma, X.L., Willette, R.N. & Yue, T.L. (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovascular Research, 61, 548–558.
8. Belcher, J.D., Bryant, C.J., Nguyen, J., Bowlin, P.R., Kielbik, M.C., Bischof, J.C., Hebbel, R.P. & Vercellotti, G.M. (2003) Transgenic sickle mice have vascular inflammation. Blood, 101, 3953–3959.
9. Bereal-Williams, C., Machado, R.F., McGowan, V. 2nd, Chi, A., Hunter, C.J., Kato, G.J., Hunter, L., Dalby, C.K., Hauser, K.P., Tailor, A. & Cannon, R.O. 3rd (2012) Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica, 97, 1768–1770.
10. Bhagat, S., Patra, P.K. & Thakur, A.S. (2012) Association of inflammatory biomarker C-reactive protein, lipid peroxidation and antioxidant capacity marker with HbF level in sickle cell disease patients from Chattisgarh. Indian Journal of Clinical Biochemistry, 27, 394–399.
11. Blake, G.J. & Ridker, P.M. (2000) Are statins anti-inflammatory? Current Controlled Trials in Cardiovascular Medicine, 1, 161–165.
12. Blann, A.D., Mohan, J.S., Bareford, D. & Lip, G.Y. (2008) Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. Journal of Thrombosis and Thrombolysis, 25, 185–189.
13. Braman, R.S. & Hendrix, S.A. (1989) Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Analytical Chemistry, 61, 2715–2718.
14. Brown, M.D., Allen, J.C., Van Stavern, G.P., Newman, N.J. & Wallace, D.C. (2001) Clinical, genetic, and biochemical characterization of a Leber hereditary optic neuropathy family containing both the 11778 and 14484 primary mutations. American Journal of Medical Genetics, 104, 331–338.
15. Bustos, C., Hernandez-Presa, M.A., Ortego, M., Tunon, J., Ortega, L., Perez, F., Diaz, C., Hernandez, G. & Egido, J. (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Journal of the American College of Cardiology, 32, 2057–2064.
16. Canalli, A.A., Franco-Penteado, C.F., Saad, S.T., Conran, N. & Costa, F.F. (2008) Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica, 93, 605–609.
17. Canalli, A.A., Proenca, R.F., Franco-Penteado, C.F., Traina, F., Sakamoto, T.M., Saad, S.T., Conran, N. & Costa, F.F. (2011) Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica, 96, 526–533.
18. Chi, J.T., Chang, H.Y., Haraldsen, G., Jahnsen, F.L., Troyanskaya, O.G., Chang, D.S., Wang, Z., Rockson, S.G., van de Rijn, M., Botstein, D. & Brown, P.O. (2003) Endothelial cell diversity revealed by global expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 100, 10623–10628.
19. Conran, N., Fattori, A., Saad, S.T. & Costa, F.F. (2004) Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. American Journal of Hematology, 76, 343–347.
20. Dampier, C., Ely, E., Eggleston, B., Brodecki, D. & O'Neal, P. (2004) Physical and cognitive-behavioral activities used in the home management of sickle pain: a daily diary study in children and adolescents. Pediatric Blood & Cancer, 43, 674–678.
21. De Caterina, R., Libby, P., Peng, H.B., Thannickal, V.J., Rajavashisth, T.B., Gimbrone, M.A. Jr, Shin, W.S. & Liao, J.K. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation, 96, 60–68.
22. Devaraj, S., Chan, E. & Jialal, I. (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism, 91, 4489–4496.
23. Duits, A.J., Pieters, R.C., Saleh, A.W., van Rosmalen, E., Katerberg, H., Berend, K. & Rojer, R.A. (1996) Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clinical Immunology and Immunopathology, 81, 96–98.
24. Dworkis, D.A., Klings, E.S., Solovieff, N., Li, G., Milton, J.N., Hartley, S.W., Melista, E., Parente, J., Sebastiani, P., Steinberg, M.H. & Baldwin, C.T. (2010) Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. American Journal of Hematology, 86, 220–223.
25. Elshal, M.F. & McCoy, J.P. (2006) Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods, 38, 317–323.
26. Florentin, M. & Elisaf, M.S. (2012) Simvastatin interactions with other drugs. Expert Opinion on Drug Safety, 11, 439–444.
27. Giorgi, M.A., Caroli, C., Arazi, H.C. & Di Girolamo, G. (2011) Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opinion on Pharmacotherapy, 12, 1499–1509.
28. Grip, O., Janciauskiene, S. & Lindgren, S. (2002) Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflammation Research, 51, 58–62.
29. Gurkan, E., Tanriverdi, K. & Baslamisli, F. (2005) Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Annals of Hematology, 84, 71–75.
30. Hatzipantelis, E.S., Pana, Z.D., Gombakis, N., Taparkou, A., Tzimouli, V., Kleta, D., Zafeiriou, D.J., Garipidou, V., Kanakoudi, F. & Athanassiou, M. (2013) Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. International Journal of Hematology, 98, 158–163.
31. Hebbel, R.P. (2004) Special issue of microcirculation: examination of the vascular pathobiology of sickle cell anemia. Microcirculation, 11, 99–100.
32. Hebbel, R. & Mohandas, N. (1994) Sickle Cell Adherence. Raven Press, New York.
33. Hebbel, R.P. & Vercellotti, G.M. (1997) The endothelial biology of sickle cell disease. Journal of Laboratory and Clinical Medicine, 129, 288–293.
34. Holschermann, H., Schuster, D., Parviz, B., Haberbosch, W., Tillmanns, H. & Muth, H. (2006) Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis, 185, 240–245.
35. Hoppe, C., Kuypers, F., Larkin, S., Hagar, W., Vichinsky, E. & Styles, L. (2011) A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. British Journal of Haematology, 153, 655–663.
36. Jacob, E., Stinson, J., Duran, J., Gupta, A., Gerla, M., Ann Lewis, M. & Zeltzer, L. (2012) Usability testing of a Smartphone for accessing a web-based e-diary for self-monitoring of pain and symptoms in sickle cell disease. Journal of Pediatric Hematology/Oncology, 34, 326–335.
37. Jacob, E., Duran, J., Stinson, J., Lewis, M.A. & Zeltzer, L. (2013a) Remote monitoring of pain and symptoms using wireless technology in children and adolescents with sickle cell disease. Journal of the American Association of Nurse Practitioners, 25, 42–54.
38. Jacob, E., Pavlish, C., Duran, J., Stinson, J., Lewis, M.A. & Zeltzer, L. (2013b) Facilitating pediatric patient-provider communications using wireless technology in children and adolescents with sickle cell disease. Journal of Pediatric Health Care, 27, 284–292.
39. Jacob, E., Mack, A.K., Savedra, M., Van Cleve, L. & Wilkie, D.J. (2014) Adolescent pediatric pain tool for multidimensional measurement of pain in children and adolescents. Pain Management Nursing, 15, 694–706.
40. Jain, M.K. & Ridker, P.M. (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews. Drug Discovery, 4, 977–987.
41. Jiang, Z., Gong, R.R., Qiu, L., Wang, Q., Su, M., Liu, X.J., Hu, M.S., Lin, J. & Fang, D.Z. (2014) Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials. Clinical Drug Investigation, 34, 599–608.
42. Kanavaki, I., Makrythanasis, P., Lazaropoulou, C., Kattamis, A., Tzanetea, R., Kalotychou, V., Rombos, I. & Papassotiriou, I. (2012) Adhesion molecules and high-sensitivity C-reactive protein levels in patients with sickle cell beta-thalassaemia. European Journal of Clinical Investigation, 42, 27–33.
43. Kato, G.J., Martyr, S., Blackwelder, W.C., Nichols, J.S., Coles, W.A., Hunter, L.A., Brennan, M.L., Hazen, S.L. & Gladwin, M.T. (2005) Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 130, 943–953.
44. Kato, G.J., Hebbel, R.P., Steinberg, M.H. & Gladwin, M.T. (2009) Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology, 84, 618–625.
45. Kaul, D.K., Liu, X.D., Choong, S., Belcher, J.D., Vercellotti, G.M. & Hebbel, R.P. (2004) Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. American Journal of Physiology: Heart and Circulatory Physiology, 287, H293–H301.
46. Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Szarek, M., Waters, D.D., Libby, P. & Ganz, P. (2008) Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 142–147.
47. Koh, K.K. (2000) Effects of HMG-CoA reductase inhibitor on hemostasis. International Journal of Cardiology, 76, 23–32.
48. Kollander, R., Solovey, A., Milbauer, L.C., Abdulla, F., Kelm, R.J. Jr & Hebbel, R.P. (2010) Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Translational Research: The Journal of Laboratory and Clinical Medicine, 155, 170–177.
49. Krishnan, S., Setty, Y., Betal, S.G., Vijender, V., Rao, K., Dampier, C. & Stuart, M. (2010) Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. British Journal of Haematology, 148, 797–804.
50. Lamarre, Y., Romana, M., Lemonne, N., Hardy-Dessources, M.D., Tarer, V., Mougenel, D., Waltz, X., Tressieres, B., Lalanne-Mistrih, M.L., Etienne-Julan, M. & Connes, P. (2014) Alpha thalassemia protects sickle cell anemia patients from macro-albuminuria through its effects on red blood cell rheological properties. Clinical Hemorheology and Microcirculation, 57, 63–72.
51. Laufs, U. (2003) Beyond lipid-lowering: effects of statins on endothelial nitric oxide. European Journal of Clinical Pharmacology, 58, 719–731.
52. Liuni, A., Luca, M.C., Gori, T. & Parker, J.D. (2010) The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. Clinical Hemorheology and Microcirculation, 45, 161–167.
53. Lopez, B.L., Barnett, J., Ballas, S.K., Christopher, T.A., Davis-Moon, L. & Ma, X. (1996) Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Academic Emergency Medicine, 3, 1098–1103.
54. Lopez, B.L., Davis-Moon, L., Ballas, S.K. & Ma, X.L. (2000) Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis. American Journal of Hematology, 64, 15–19.
55. Makis, A.C., Hatzimichael, E.C., Stebbing, J. & Bourantas, K.L. (2006) C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Archives of Internal Medicine, 166, 366–368.
56. van der Meij, E., Koning, G.G., Vriens, P.W., Peeters, M.F., Meijer, C.A., Kortekaas, K.E., Dalman, R.L., van Bockel, J.H., Hanemaaijer, R., Kooistra, T., Kleemann, R. & Lindeman, J.H. (2013) A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS ONE, 8, e53882.
57. Mohan, J.S., Lip, G.Y., Wright, J., Bareford, D. & Blann, A.D. (2005) Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagulation and Fibrinolysis, 16, 209–214.
58. Moshage, H. (1997) Nitric oxide determinations: much ado about NO.-thing? Clinical Chemistry, 43, 553–556.
59. Nohria, A., Grunert, M.E., Rikitake, Y., Noma, K., Prsic, A., Ganz, P., Liao, J.K. & Creager, M.A. (2006) Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circulation Research, 99, 1426–1432.
60. O'Driscoll, G., Green, D. & Taylor, R.R. (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 1126–1131.
61. Okpala, I., Daniel, Y., Haynes, R., Odoemene, D. & Goldman, J. (2002) Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. European Journal of Haematology, 69, 135–144.
62. Ortego, M., Bustos, C., Hernandez-Presa, M.A., Tunon, J., Diaz, C., Hernandez, G. & Egido, J. (1999) Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 147, 253–261.
63. Osarogiagbon, U.R., Choong, S., Belcher, J.D., Vercellotti, G.M., Paller, M.S. & Hebbel, R.P. (2000) Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 96, 314–320.
64. Owusu-Ansah, A., Ihunnah, C.A., Walker, A.L. & Ofori-Acquah, S.F. (2016) Inflammatory targets of therapy in sickle cell disease. Translational Research: The Journal of Laboratory and Clinical Medicine, 167, 281–297.
65. Palmer, R.M., Ashton, D.S. & Moncada, S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 333, 664–666.
66. Piechota-Polanczyk, A. & Jozkowicz, A. (2016) The role of statins in heme oxygenase-1 activation in cardiovascular diseases. Current Drug Targets, 17, 2016 Apr 1. [Epub ahead of print] DOI: 10.2174/1389450117666160401123600
67. Qari, M.H., Dier, U. & Mousa, S.A. (2012) Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clinical and Applied Thrombosis/Hemostasis, 18, 195–200.
68. Rees, D.C., Cervi, P., Grimwade, D., O'Driscoll, A., Hamilton, M., Parker, N.E. & Porter, J.B. (1995) The metabolites of nitric oxide in sickle-cell disease. British Journal of Haematology, 91, 834–837.
69. Rosch, J.W., Boyd, A.R., Hinojosa, E., Pestina, T., Hu, Y., Persons, D.A., Orihuela, C.J. & Tuomanen, E.I. (2010) Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. Journal of Clinical Investigation, 120, 627–635.
70. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R. & Braunwald, E. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001–1009.
71. Saleh, A.W., Hillen, H.F. & Duits, A.J. (1999) Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematologica, 102, 31–37.
72. Selvaraj, S.K., Giri, R.K., Perelman, N., Johnson, C., Malik, P. & Kalra, V.K. (2003) Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood, 102, 1515–1524.
73. Shah, S.H. & Newby, L.K. (2003) C-reactive protein: a novel marker of cardiovascular risk. Cardiology in Review, 11, 169–179.
74. Shiu, Y.T., Udden, M.M. & McIntire, L.V. (2000) Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood, 95, 3232–3241.
75. Silveira, A.A., Dominical, V.M., Lazarini, M., Costa, F.F. & Conran, N. (2013) Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity. Inflammation Research, 62, 127–132.
76. Smith, W.R., Penberthy, L.T., Bovbjerg, V.E., McClish, D.K., Roberts, J.D., Dahman, B., Aisiku, I.P., Levenson, J.L. & Roseff, S.D. (2008) Daily assessment of pain in adults with sickle cell disease. Annals of Internal Medicine, 148, 94–101.
77. Smith, W.R., Ballas, S.K., McCarthy, W.F., Bauserman, R.L., Swerdlow, P.S., Steinberg, M.H. & Waclawiw, M.A. & Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (2011) The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Medicine, 12, 697–705.
78. Solovey, A.A., Solovey, A.N., Harkness, J. & Hebbel, R.P. (2001) Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood, 97, 1937–1941.
79. Solovey, A., Kollander, R., Shet, A., Milbauer, L.C., Choong, S., Panoskaltsis-Mortari, A., Blazar, B.R., Kelm, R.J. Jr & Hebbel, R.P. (2004) Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 104, 840–846.
80. Takemoto, M., Sun, J., Hiroki, J., Shimokawa, H. & Liao, J.K. (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation, 106, 57–62.
81. Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C. & Stefanadis, C. (2014) Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. Journal of the American College of Cardiology, 63, 2491–2502.
82. Verger, E., Schoevaert, D., Carrivain, P., Victor, J.M., Lapoumeroulie, C. & Elion, J. (2014) Prior exposure of endothelial cells to hydroxycarbamide alters the flow dynamics and adhesion of sickle red blood cells. Clinical Hemorheology and Microcirculation, 57, 9–22.
83. Wang, H.R., Li, J.J., Huang, C.X. & Jiang, H. (2005) Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clinica Chimica Acta, 353, 53–60.
84. Yawn, B.P., Buchanan, G.R., Afenyi-Annan, A.N., Ballas, S.K., Hassell, K.L., James, A.H., Jordan, L., Lanzkron, S.M., Lottenberg, R., Savage, W.J., Tanabe, P.J., Ware, R.E., Murad, M.H., Goldsmith, J.C., Ortiz, E., Fulwood, R., Horton, A. & John-Sowah, J. (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA, 312, 1033–1048.